CETP

Dr Reddy's starts phase 2 study with CETP inhibitor in dyslipidemia patients

Dr Reddy's Laboratories announced the initiation of dosing with DRL-17822 in patients with diagnosis of type 2 dyslipidemia. DRL-17822 is a selective, orally bioavailable inhibitor of cholesteryl ester transfer protein (CETP), for the treatment and/or prevention of dyslipidemia, atherosclerosis and associated cardiovascular disease.

CETP | 05 September 2011

• Dr Reddy
• CETP